Document is current
Any future updates will be listed below
-
Authors
Òdena, Andreu
Monserrat, Laia
Brasó-Maristany, Fara
García-Galea, Eduardo
Casals, Eloi
Molina, Cristina
Herencia-Ropero, Andrea
Pedretti, Flaminia
Domènech, Heura
Guzmán, Marta
Rodríguez, Olga
Grueso, Judit
Esteve-Codina, Anna
Dienstmann, Rodrigo
Chandarlapaty, Sarat
Fan, Pang-Dian
Suto, Fumitaka
Oliveira, Mafalda
Prat, Aleix
Serra, Violeta
-
Funding
Funding for this research was provided by:
Agència de Gestió d'Ajuts Universitaris i de Recerca (2022 FI_B 00664, 2019 FI_B 01199, 2021 SGR 01156, 2021 SGR 01510)
Fundación Científica Asociación Española Contra el Cáncer (INVES21943BRAS)
Fundación Contigo (HIMALAIA)
Generalitat de Catalunya (PERIS SLT017/20/000081)
'la Caixa' Foundation (LCF/BQ/DI19/11730051)
Ministerio de Ciencia y Tecnología (PRE2021-099087)
Instituto de Salud Carlos III (PI22/01017, PI20/00892)
Memorial Sloan-Kettering Cancer Center (P30 CA008748)
Breast Cancer Research Foundation (BCRF-22-198)
Beca Marta Santamaría
Fundación CRIS contra el Cáncer (PR_EX_2021-14)
Fundación Fero (ONCOXXI21)
Asociacion Española Cáncer de Mama Metastásico (IV Premios M. Chiara Giorgetti, III Metapremio M. Chiara Giorgetti 2021)
RESCUER (847912)
- License Information
-
More Information
Article History
Received: 17 June 2025
Accepted: 22 October 2025
First Online: 21 November 2025
Competing interests
: F. Brasó-Maristany reports part-time employment from Reveal Genomics, and has patents filed: PCT/EP2022/086493, PCT/EP2023/060810, EP23382703 and EP23383369. R. Dienstmann declares advisory role for Roche, Foundation Medicine, AstraZeneca, Pfizer, received a speaker’s fee from Roche, Foundation Medicine, GuardantHealth, Ipsen, Amgen, Servier, Sanofi, Libbs, Merck Sharp & Dohme, Lilly, AstraZeneca, Johnson and Johnson, Takeda, Bristol Myers Squibb, GlaxoSmithKline, Gilead, Pfizer, research grants from Merck, Novartis, Daiichi-Sankyo, GlaxoSmithKline, Pfizer and AstraZeneca, and is investor in Trialing Health, S.L. P-D. Fang and F. Suto are full-time employees at Daiichi Sankyo Inc. S. Chandarlapaty has received institutional grant/funding from Daiichi-Sankyo and AstraZeneca, Shares in Totus Medicines, and consultation/Ad board/Honoraria from Daiichi-Sankyo, AstraZeneca, Lilly, and Casdin Capital. M. Oliveira received research grants from AstraZeneca, Ayala Pharmaceuticals, Boehringer-Ingelheim, Genentech, Gilead, GSK, Immutep, Roche, Seagen and Zenith Epigenetics. M. Oliveira reports advisory and consulting role from AstraZeneca, Cureos Science, Daiichi-Sankyo / AstraZeneca, Gilead, iTEOS, Lilly, MSD, Relay Therapeutics, Roche and Seagen. M. Oliveira received honoraria from AstraZeneca, Eisai, Gilead, Libbs, Lilly, MSD, Novartis, Pfizer, Roche, Seagen. M. Oliveira received travel grants from AstraZeneca, Eisai, Gilead, Pierre-Fabre. M. Oliveira serves as the President of the SOLTI Breast Cancer Group. A. Prat reports advisory and consulting fees from AstraZeneca, Roche, Pfizer, Novartis, Daiichi Sankyo, and Peptomyc, lecture fees from AstraZeneca, Roche, Novartis, and Daiichi Sankyo, institutional financial interests from AstraZeneca, Novartis, Roche, and Daiichi Sankyo; stockholder and employee of Reveal Genomics; patents filed PCT/EP2016/080056, PCT/EP2022/086493, PCT/EP2023/060810, EP23382703 and EP23383369. V. Serra reports research grants from AstraZeneca and personal fees and/or non-financial support from AstraZeneca and GSK. The remaining authors declare that they have no competing interests.
